AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Nurix Therapeutics, Inc.
Video analysis: NRIX
All videosNo video analysis for this stock yet. Request one from our team.
News: NRIX
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
Nurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Tuesday, September 8, 2026, at 3:00 p.m.
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case
Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. NRIX's financial runway is extended to ~3.5 years, reducing near-term dilution risk and enabling multi-indication expansion without sacrificing U.S. economics. Bexobrutideg's Phase 1 data show high response rates in CLL/SLL, with a pivotal Phase 3 trial aiming to demonstrate superiority over pirtobrutinib.
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and inflammatory diseases, today announced that Wes Burwell has joined Nurix as its Chief Human Resources Officer (CHRO).
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade
Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after Royal Bank Of Canada raised their price target on the stock from $33.00 to $36.00. Royal Bank Of Canada currently has an outperform rating on the stock. Nurix Therapeutics traded as high as $26.04 and
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well as potential royalties, and retains a U.S. co-development and co-promotion option BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following the initiation by its collaborator, Sanofi, of the Phase 1 first-in-human clinical trial of SAR448272/NX-3911, an oral STAT6 degrader.
